NodThera’s NT-0796, an investigational oral therapy for Parkinson’s disease, reduced several inflammatory markers in elderly volunteers in seven days, according to initial data from a Phase Ib/IIa study. Parkinson’s patients are now being recruited for the trial’s second phase to determine the therapy’s impact on a panel of clinical…
Gb Sciences has completed a study testing its experimental cannabinoid-based therapy for Parkinson’s disease in rodents. The study, which was conducted at the University of Lethbridge, in Canada, tested a range of doses of the investigational therapy, establishing how long it takes each dose to have an effect…
Internalized, experienced, or anticipated stigma have significant impacts on employment experiences for people with Parkinson’s disease, according to a recent study. In semi-structured interviews with patients, a researcher identified that patients felt hesitant to disclose their diagnosis in the workplace or ask for disability-related accommodations, often due to a…
Higher levodopa doses were associated with a drop in blood pressure among older Parkinson’s patients, those with 65 or more years, in the early and middle stages of the disease, a study reported. Cognitive impairment was identified as a risk factor for a sudden blood pressure drop when…
The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s software called Vercise Neural Navigator 5, which provides visual guidance on how to best program deep brain stimulation (DBS) settings for Parkinson’s disease. The improved software features an enhanced user-friendly interface that presents simplified patient data and…
Plant compounds extracted from the Amomum subulatum fruit, also known as greater cardamom, were found to ease Parkinson’s disease-like symptoms — lessoning tremors and reducing muscular rigidity — in a rat model of features that are hallmarks of the neurodegenerative disorder. The greater cardamom extracts, given orally, worked to increase…
Imaging software developed by Braintale may distinguish Parkinson’s disease from atypical parkinsonism based on measures of early changes in the brain’s white matter, aiding in better diagnoses and disease treatment development. That’s according to initial results from a study into biomarkers on magnetic resonance…
The Parkinson Voice Project (PVP)’s SPEAK OUT! Therapy & Research Center at Northeastern University will receive a $280,000 PVP grant for training, services, equipment, and supplies over the next five years. The four-week program, running at the university’s Speech-Language and Hearing Center for more than two years,…
Using a smartwatch to track how fast people can move may help identify who’s at risk for Parkinson’s disease up to seven years before symptoms become evident and doctors make a diagnosis, a study suggests. Wearing the smartwatch for a week was enough to feed an artificial intelligence (AI)-powered…
Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could benefit people with a range of neurological conditions, including Parkinson’s disease. The safety and efficacy trial, approved to take place in Israel, is expected to begin enrolling children with…
Get regular updates to your inbox.
